Plain-English translation of NCT07367724 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called Ademetionine in patients with obstructive hypertrophic cardiomyopathy (oHCM), a condition where the heart muscle becomes thickened and blocks blood flow. Half the participants will receive the medication, and half will receive a placebo (inactive pill), to see whether this treatment helps people exercise better, feel better, and have improved heart function. The study will follow participants for 16 weeks to check if the medication is safe and effective.
Obstructive hypertrophic cardiomyopathy can severely limit exercise and cause heart failure symptoms, and current treatments don't work well enough for everyone. Researchers are testing this medication to see if it could be a new option to help patients breathe easier, exercise more, and improve their quality of life.
You likely qualify if…
You likely don't qualify if…
If you join, you'll be randomly assigned to receive either the new medication or a placebo pill — neither you nor the researchers will know which one you're getting (this is called double-blind). You'll visit the clinic every 4 weeks for 16 weeks, where doctors will check your heart health, ask about your symptoms and exercise ability, and monitor for any side effects. The study will use heart imaging and exercise tests to measure whether the medication helps you feel better and function more easily.
AI-generated summary from trial data · Aug 9, 2026 · Not medical advice
China